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0022-2836/$ - see front matter © 2007 EBifunctional human PAPS synthetase (PAPSS) catalyzes, in a two-step
process, the formation of the activated sulfate carrier 3′-phosphoadenosine
5′-phosphosulfate (PAPS). The first reaction involves the formation of the 5′-
adenosine phosphosulfate (APS) intermediate from ATP and inorganic
sulfate. APS is then further phosphorylated on its 3′-hydroxyl group by an
additional ATP molecule to generate PAPS. The former reaction is catalyzed
by the ATP-sulfurylase domain and the latter by the APS-kinase domain.
Here, we report the structure of the APS-kinase domain of PAPSS isoform 1
(PAPSS1) representing the Michaelis complex with the products ADP-Mg
and PAPS. This structure provides a rare glimpse of the active conformation
of an enzyme catalyzing phosphoryl transfer without resorting to substrate
analogs, inactivating mutations, or catalytically non-competent conditions.
Our structure shows the interactions involved in the binding of the
magnesium ion and PAPS, thereby revealing residues critical for catalysis.
The essential magnesium ion is observed bridging the phosphate groups of
the products. This function of the metal ion is made possible by the DGDN-
loop changing its conformation from that previously reported, and
identifies these loop residues unambiguously as a Walker B motif.
Furthermore, the second aspartate residue of this motif is the likely
candidate for initiating nucleophilic attack on the ATP γ-phosphate group
by abstracting the proton from the 3′-hydroxyl group of the substrate APS.
We report the structure of the APS-kinase domain of human PAPSS1 in
complex with two APS molecules, demonstrating the ability of the ATP/
ADP-binding site to bind APS. Both structures reveal extended N termini
that approach the active site of the neighboring monomer. Together, these
results significantly increase our understandings of how catalysis is
achieved by APS-kinase.© 2007 Elsevier Ltd. All rights reserved.Keywords: PAPS synthetase; APS-kinase domain; phosphoryl transfer;
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The availability of a high-energy sulfuryl group
donor molecule is essential for all sulfonation
reactions.1 In higher organisms, sulfate activation
is catalyzed by the bifunctional PAPS synthetase
that contains both an ATP-sulfurylase (ATPS)
domain and an APS-kinase (APSK) domain. The
former activates inorganic sulfate by reaction with
ATP to give adenosine-5′-phosphosulfate (APS) and
pyrophosphate; APS is subsequently phosphory-
lated by the APSK domain to yield the universal
high-energy sulfuryl donor 3′-phosphoadenosine-
5′-phosphosulfate (PAPS).d.
489Structure of APS-Kinase Domain of Human PAPSS1In mammalian cells, PAPS is absolutely required
for the sulfonation of proteins, hormones, neuro-
transmitters, carbohydrates, lipids, drugs and xeno-
biotics. All enzymes that catalyze sulfonation, called
sulfotransferases, utilize PAPS as the sulfuryl
donor.2 The fact that PAPS synthetase (PAPSS) is
the sole source of PAPS makes this enzyme indis-
pensable for all cells. Humans express two isoforms
of PAPSS that are 78% identical.3 Isoform 1, PAPSS1,
is highly expressed in brain and skin, while PAPSS2
is the predominant form in liver and cartilage.4,5
Mutations in PAPSS2 have been associated with
several diseases in mice and humans (murine
brachymorphism,6,7 human spondyloepimetaphy-
seal dysplasia,8 and some forms of osteoarthritis9,10).
In the majority of lower organisms and plants the
ATP-sulfurylase and APS-kinase activities are pre-
sent on two separate proteins. In contrast, these
activities are combined into a single polypeptide in
mammals. The biological implications for the
fusion of the ATPS and APSK genes are still
unclear. It had been proposed that a bifunctional
enzyme would enable the intermediate APS to be
channeled between the two active centers.11 How-
ever, recent extensive kinetic analysis12 and the
structure of the bifunctional PAPSS113 reveal the
absence of such a channel between the two active
sites. Furthermore, experiments employing equi-
molar amounts of monofunctional proteins (ATPS
and APSK domains cloned and expressed sepa-
rately) showed that the mixture is equally efficient
in catalyzing the overall reaction as the bifunc-
tional protein itself.14 Moreover, switching the order
of the domains within a single polypeptide chain
maintains a functional protein.14 These observations
suggest that each domain functions independently,
and support the proposal that fusion of the two
activities onto a single polypeptide is mainly for
attaining coordinated expression.15 However, one
cannot discard the possibility that ligand-induced
conformational changes allow for some measure of
coordination between the two domains. As a first
step towards increasing our understanding of these
physiologically essential bifunctional enzymes we
have undertaken experiments to structurally char-
acterize the enzymatically active APSK domain of
PAPSS1.
Kinetic studies done with the homologous mono-
functional APS-kinase from Penicillium chrysogenum
have established an ordered reaction mechanism,
in which the enzyme first binds ATP-Mg, and
then binds the second substrate APS.16 Upon com-
pletion of phosphoryl transfer, PAPS leaves first,
followed by ADP. The proposed kinetic mechanism
is supported also by experiments based on the
accessibility of the active site for chemical modifi-
cations,17 or susceptibility to proteolysis when
incubated with different sets of nucleotides,18
suggesting that substrate binding is accompanied
by significant conformational changes. Crystal
structures of P. chrysogenum APSK without any
nucleotides in the active site,18 or those complexed
with ADP, or the combination of ADP and APS,19reveal the predicted conformational changes in-
duced by nucleotide binding.
One of the intriguing hallmarks of this enzyme is
the pronounced substrate inhibition with APS.
Studies on APSK from P. chrysogenum,16 rat,20 and
Arabidopsis thaliana21 have shown that this inhibition
is uncompetitive in nature, suggesting the formation
of the dead-end E-ADP-APS complex. This complex
is predicted to formafter completion of the enzymatic
reaction, when PAPS leaves the active site and APS
rebinds to the same site before ADP dissociation.
Our current structural information on the APSK
domain of human PAPSS1 is limited to structures
solved in the context of bifunctional enzyme.13
These PAPSS1 structures were obtained by soaking
different ligands to the same crystal form and,
unexpectedly, all show an asymmetry between the
two APSK domains that form the PAPSS1 dimer.
These data were interpreted such that asymmetry in
the PAPSS1 APSK domain is an intrinsic feature of
the human enzyme.13 This asymmetry is in contrast
to structures of the P. chrysogenum APSK that show
equivalent monomers.18,19 An alternative expla-
nation for the observed asymmetry in the ASPK
domain of PAPSS1 could be the presence of the ATP-
sulfurylase domain, or simply a manifestation of the
crystallization conditions. Additional open ques-
tions regarding the APSK domain concern the
binding mode of the essential magnesium ion,17
and of the transferred phosphoryl group. Finally,
although several experiments suggest the formation
of E-ADP-APS as the inhibitory complex, the
question remains of whether APS, due to its high
structural resemblance to ADP, can also bind at the
ATP/ADP-binding site, thereby forming an inhibi-
tory E-APS-APS complex. To address these issues,
we solved the crystal structures of the PAPSS1 APSK
domain in complex with APS, and in complex with
the products PAPS and ADP. Interestingly, both
structures of isolated domain, obtained in different
crystal forms, reveal symmetrical dimers. The
structure of the Michaelis product complex (ADP
plus PAPS), which includes the magnesium ion,
reveals how the ion serves to organize the active site
residues into a productive conformation and iden-
tifies residues involved in binding of the transferred
phosphate group. The structure with APS confirms
that APS can indeed bind concomitantly to the APS
and ATP/ADP sites. In addition, in both complexes
we can model previously unseen N-terminal resi-
dues that are positioned close to the nucleotides of
the neighboring monomer. Together, these results
increase our structural and functional understand-
ing of this important enzyme.Results
Overall structure
The APS-kinase (APSK) domain (residues 25–227)
of human bifunctional PAPS synthetase 1 was crys-
490 Structure of APS-Kinase Domain of Human PAPSS1tallized in complex with APS, and with ADP plus
PAPS. The APS complex crystallized in space group
C2with eightmolecules in the asymmetric unit. Initial
phases were obtained by molecular replacement
using a truncated structure of the P. chrysogenum
APS-kinase solved in complex with ADP and APS as
the search model.19 The model was refined at 2.05 Å
resolution to a final R-factor of 22.3% and Rfree of
28.2%. Two APS molecules per monomer, one at
the APS-binding site and one at the phosphoryl
donor-binding site, were clearly observed in the
electron density maps. In six of the eight mono-Figure 1. The APSK domain of human bifunctional PAPSS
fold as that observed in the context of the bifunctional enzyme
orange) in complex with ADP and PAPS (maroon). The mag
yellow sphere. Note that the N-terminal residues of one mono
(b) Overlay of the APSK domain crystallized with ADP and PA
the context of the full length PAPSS1 (gray, chain B in PDB ent
0.44 Å over 201 common Cα atoms; between our structures a
differences are: the conformation of the DGDN-loop (circle) a
terminus (rectangle). These N-terminal residues approach the
monomer are included for orientation purposes).mers, electron density extending to the first
residue present in our construct allowed visualiza-
tion of the N-terminal region. In addition, a confor-
mation not seen before for a conserved region
(DGDN-loop) revealed its role in magnesium bind-
ing (see below).
The APS-kinase domain in complex with ADP and
PAPS crystallized in space group P21 with two
molecules in the asymmetric unit. The maximum
resolution for this data set was 1.9 Å. The starting
model used to solve the ADP-PAPS complex struc-
ture was the above APS complex. After alternating1 forms a symmetrical dimer and adopts the same overall
. (a) Ribbon diagram of the APSK dimer (in light blue and
nesium ion bridging the two nucleotides is depicted as a
mer approach the active site of the neighboring monomer.
PS (light blue), with APS (red), and with ADP and APS in
ry 1XNJ). The rmsd for the two structures reported here is
nd 1XNJ, it is 0.57–0.62 Å over 175–191 atoms. Important
nd our ability to model nine additional residues at the N
active site of the second monomer (the nucleotides of that
491Structure of APS-Kinase Domain of Human PAPSS1rounds of model building and refinement, the struc-
ture converged to anR-factor of 18.7% and anRfree of
23.6%. Excellent electron density for the two nucleo-
tides, including the essential magnesium ion, was
observed. The APS-kinase dimer in complex with
ADP and PAPS is shown in Figure 1(a). The
N-terminal region and themagnesium-binding com-
petent conformation of the DGDN-loop resembled
that present in the APS-APS complex. For both the
APS-APS and the ADP-PAPS structures, all main
chain dihedral angles are found in the allowed
regions of the Ramachandran plot. Data collection
and refinement statistics are presented in Table 1.
The overall fold of both structures is the same as
that described for the APSK domain of the full-
length PAPSS113 (Figure 1(b)) and the APSK domain
from PAPSS2 (PDB ID 2AX4). Interestingly, in the
reported structures of the full-length PAPSS1, theTable 1. Data collection and refinement statistics
ADP-PAPS APS-APS
A. Data collection
Beamline APS, SERCAT-BM APS, SERCAT-BM
Wavelength (Å) 1.000 0.9594
Unit cell parameters
a (Å) 51.40 181.19
b (Å) 63.32 69.03
c (Å) 61.69 150.61
β (deg.) 114.38 116.65
Space group P21 C2
No. molecules/a.u. 2 8
Resolution limit (Å) 20–1.9 10–2.05
Measured reflections 156,400 376,976
Unique reflections 27,832 101,066
Completeness (%) 97.5 (94.5) 83.6 (92.9)
I/σI 18.83 (9.30) 12.4 (4.36)
Rsym 7.1 (14.8) 8.2 (24.0)
B. Refinement




R-factor 0.187 (0.205) 0.223 (0.234)
Rfree 0.236 (0.306) 0.282 (0.324)
No. protein residues 406 1594
No. water molecules 252 822
No. nucleotides 4 16
No. ions 6 6
rmsd from
ideal geometry
Bond lengths (Å) 0.012 0.011













Disallowed regions (%) 0.0 0.0
PDB ID 2OFX 2OFW
Rsym=∑|I–〈I〉|/∑ I.
Data in parentheses are for the last shell: ADP/PAPS,=1.90–2.01
Å; APS/APS=2.05–2.10 Å.
Rcryst=∑||Fobs|–|Fcalc||/∑|Fobs|, 10% randomly omitted
reflections were used for Rfree.APS-kinase domain exhibited differences between
the molecules that form the physiological dimer: one
molecule contained nucleotide(s) and the second
was empty.13 In contrast, apart from small differ-
ences between monomers in the APS-APS complex,
our structures reveal a symmetric dimer (rmsd
between the two monomers of the ADP-PAPS
structure is 0.19 Å, and range from 0.26–0.65 Å for
the eight monomers of the APS-APS structure).
Consistent with our results, the structure of the
isolated APSK domain from PAPSS2 also contains a
symmetrical dimer with one ADP molecule in each
of the monomer's active sites (PDB ID 2AX4). The
presence of magnesium in our structures has
ramifications for the nucleotides that it directly
interacts with, and for the conformation of the
DGDN-loop and the N terminus. The change in
conformation of the DGDN-loop in comparison to
that seen in the absence of magnesium (circle in
Figure 1(b)) allows the N terminus to adopt a stable
conformation not previously seen (rectangle in
Figure 1(b)). Note that the N terminus of one
monomer approaches the nucleotides bound to the
counterpart monomer.
ADP binding
It has been observed in human bifunctional
PAPSS1 that the base of the ADP (ADP was present
in only one of the subunits) adopts the syn
conformation. This is in contrast to the anti ADP
conformation observed in structures of the P.
chrysogenum APSK. The electron density for the
ADP in our ADP-PAPS complex structure was
unambiguous for the phosphate moieties but
revealed two possible conformations for the sugar
and the base. One conformation approximates the
previously reported syn conformation and the other
the anti conformation (Figure 2(a)).
Interactions of the adenine base and the protein
are limited only to π-stacking between Arg168 and
Val209, and a sole hydrogen bond between the main
chain carbonyl group of Cys207 and NH2 of the
adenine. The interactions are maintained in both the
syn and anti base conformations (Figure 2(b)).
Therefore, these non-conformationally discriminat-
ing interactions and the observed electron density
suggest that both the syn and anti ADP forms are
present in our crystals at an approximately equal
ratio. In contrast, the ADP phosphate groups are
firmly positioned by main chain interactions with
P-loop residues, and exhibit a single conformation.
Interestingly, two P-loop side-chains, Ser61 and
Lys65, also interact with the 3′-phosphate group of
the PAPS molecule (Figures 2(b) and 3). A paucity of
interactions with the ribose hydroxyl groups sug-
gests that both oxy and deoxy nucleotides can be
equally efficient as phosphoryl donors.
PAPS binding
This is the first report of an APSK with PAPS
bound in the active site. The electron density un-
Figure 2. Binding of nucleotides and magnesium in the ADP-PAPS complex. (a) ADP in its modeled syn and anti
conformation with the simulated annealing composite omit map calculated with the coefficients 2Fobs–Fcalc (contoured at
1.3 σ). Invoking a mixture of the two base conformations accounts best for the electron density maps. (b) Stereo view
depicting the interactions made by ADP. Nitrogen atoms are rendered in blue, oxygen in red, sulfur in yellow and
phosphorus in magenta. Protein carbon atoms are colored in light blue whereas nucleotide carbon atoms are in brown.
Water molecules are depicted as cyan spheres, and the magnesium ion with its water ligands in yellow. The anti ADP
conformation is shown as a semi-transparent model. (c) PAPS with its map as in (a) but contoured at 1.5 σ. (d) Stereo view
of the interactions made by PAPS and color coded as in (b). The N terminus that originates from the neighboringmonomer
is rendered as a semi-transparent orange coil. (e) The octahedrally coordinated magnesium with the corresponding omit
map as in (c). (f) Stereo view depicting magnesium coordination. The cation bridges the phosphate groups of ADP and
PAPS, as well as interacting with Thr66 from the protein P-loop. The remaining three ligands are water molecules. One of
the water molecules coordinated to magnesium is stabilized through interactions with Asp87 and Asp89 from the DGDN-
loop. Another water ligand is at a hydrogen bond distance to Gln31 that originates from the N terminus (orange) of the
other monomer.
492 Structure of APS-Kinase Domain of Human PAPSS1equivocally shows a 3′-phosphate group, which
differentiates PAPS from APS (Figure 2(c)). The
portion of the PAPS molecule that is common to
that of APS is observed to bind in a fashion verysimilar to that described for APS.13,19 In short, the
adenine base is in the syn conformation firmly
stacked between two conserved phenylalanine
residues (Phe185 and Phe101). The NH2 group, a
Figure 3. Distance map of the active site of APSK domain in complex with ADP plus PAPS. A representation of the
protein–nucleotides–magnesium interactions. Nucleotides are shown as thick bonds (ADP in anti conformation), main
chain protein atoms in green, side-chains in red, and magnesium and its three water ligands in yellow. Gln31 that
belongs to the N terminus of the other monomer is shown in orange. All distances are in Å.
493Structure of APS-Kinase Domain of Human PAPSS1hallmark of the adenine ring, is held in place by
an interaction with the main chain carbonyl group
of Gly184. Arg106 contributes to the stabilization
of the syn conformation by bridging the adenine
ring N1 atom and an oxygen atom of the sulfate
moiety. Oxygen atoms of the 5′-phosphosulfate
group interact with the side-chains of Arg92 and
Asn109 (residues that are disordered before APS
binding13) as well as the main chain nitrogen
atoms of amino acid residues 132 and 133 (Figures
2(d) and 3).
Notably, the side-chain of Asn27 from the N-
terminal region of the neighboring monomer is close
(∼3.5 Å) to the base of the phosphoryl acceptor. This
N-terminal region, which was not observed in pre-
vious structures, approaches the APS/PAPS bind-
ing site in our structures (depicted as a transparent
orange coil in Figure 2(d) and an opaque orange coil
in Figure 2(f)). While not interacting with PAPS
directly, the Asn27 side-chain (not shown) adopts a
position that is possible only when the base is in the
syn conformation. Since this is one of the few
conserved residues in the N-terminal region, we
examined whether it has a role in facilitating APS/
PAPS binding. Substituting Asn27 with Ala did nothave any effect on the steady-state activity of the
protein (Supplementary Data Table S1).
The PAPS ribose ring is held in position by Asp89
from the DGDN-loop through interactions with the
2′-hydroxyl and 3′-hydroxyl groups. These interac-
tions ensure that the sugar ring adopts the 2′-endo, 3′-
exo conformation. The 3′-phosphate group of PAPS
draws three different parts of the protein closer to the
APS/PAPS-binding region. This is accomplished by
an interaction with Ser61 and Lys65 from the P-loop,
which are situated in the core of the protein, with
Asp89 from the DGDN-loop, and finallywith Lys171
from the lid region. These interactions seem to
provide extra rigidity to the structure. The latter
interaction contributes to the final closure of the lid
region and provides an additional basic residue that
can participate in catalyzing phosphoryl transfer.
Overlay of the APSK domain on guanylate kinase
(a representative member of the nucleoside mono-
phosphate kinases) demonstrates that Lys171 is
positioned similarly to the lid arginine (Arg137) of
mouse guanylate kinase.22 Together, this suggests
that the conserved Lys171 interacts with the γ-
phosphate group of ATP, and guides its transfer to
the 3′-OH group of the acceptor APS.
494 Structure of APS-Kinase Domain of Human PAPSS1Magnesium binding and DGDN-loop
Excellent electron density was observed for the
octahedrally coordinated magnesium ion (Figure
2(e)). Thr66 of the P-loop (Ser in several other
organisms) forms one of the metal ligands. Two
additional ligands are provided by the phosphate
groups of ADP (β-phosphate) and PAPS (3′-phos-
phate). The remaining three magnesium ion ligands
are water molecules. Importantly, the observation of
magnesium bridging the two substrates via what
was the ATP γ-phosphate group, now at the 3′
position of PAPS, and the phosphate group corre-
sponding to the β-phosphate group of ATP (Figures
2(f) and 3), reveals the role of the metal ion in
catalyzing phosphoryl transfer (see Discussion).Figure 4. The DGDN-loop changes conformation in the pr
DGDN-loop (light blue) from the ADP–PAPS complex with th
APS complex (gray, PDB id 1XNJ). Due to the presence of m
stabilized at a conformation where Asp87 and Asp89 interact
but not the DGDN-loop in the structure lacking magnesium,
structure. The three polar interactions between main chain at
dotted orange lines with the corresponding distances in Å. Pron
Asp89 and Asn90 (black arrows). (b) Stereo view of the active
ADP plus PAPS (light blue), APS plus APS (red), and the m
presence of magnesium draws the DGDN-loop towards the a
groups (P)APS. In addition, the interaction between the PAP
nucleotide towards ADP.One of the magnesium ion water ligands is
positioned through interactions with carboxyl
groups of the highly conserved Asp87 and Asp89.
This conformation of the loop holding Asp87 and
Asp89 separated by a glycine residue (DGDN-loop)
is first observed in the structure reported here
(Figure 4(a)). The high level of conservation of the
86LDGDN90 sequence that is positioned in proxi-
mity to the active site was noted by MacRea et al.18
who suggested that this sequence is analogous to
the Walker B motif (the motif that contributes a
carboxylic acid required for magnesium-water
ligand coordination). This prediction was hard to
reconcile with the available structures, since the
predicted aspartic acid residue was too far from the
P-loop (Walker A motif), and hence the ATP-Mgesence of magnesium. (a) Stereo view of an overlay of the
e N terminus in orange and the previously reported ADP-
agnesium in the ADP–PAPS complex, the DGDN-loop is
with a magnesium water ligand. This loop conformation,
allows the N terminus to adopt the position seen in our
oms of the N terminus and the DGDN-loop are shown as
ounced differences in side-chain position are observed for
site overlay between the APSK domain in complex with
onomer containing ADP plus APS in 1XNJ (gray). The
ctive site, allowing Asp89 to interact with sugar hydroxyl
S 3′-phosphate group and the magnesium ion draws the
495Structure of APS-Kinase Domain of Human PAPSS1binding site. The authors suggested that a magne-
sium-induced conformational change would bring
the aspartic acid residue closer to the active site.
Further support of the importance of the DGDN-
loop comes from mutagenesis studies that demon-
strated a requirement for strict conservation of this
loop for enzyme activity.23 Our structures of the
APSK domain, the first to include the magnesium
ion, support the above predictions. Magnesium
binding draws the DGDN-loop towards the nucleo-
tides through the interactions with Asp87 and
Asp89 (Figure 4(a)). The pronounced conforma-
tional change of the DGDN-loop upon magnesium
binding requires the glycine residue for main chain
flexibility. In fact, the mutation associated with
brachymorphic mice, a phenotype characterized by
short stature, has been traced to a change of this
glycine residue to arginine in PAPSS2. Therefore,
our results supply a structural explanation for the
loss of APS-kinase activity that causes this disease,
directly implicating the lost ability of such a mutant
enzyme to bind magnesium.
An additional magnesium–water ligand is ob-
served to interact with the side-chain of Gln31,
which originates from the N-terminal sequence of
the other molecule (orange in Figures 2(f) and 3). To
test the importance of this interaction, we mutated
Gln31 to Ala. Surprisingly, this mutant was enzy-
matically indistinguishable from the wild-type (Sup-
plementary Data Table S1).
Apart from drawing in the DGDN-loop, the
magnesium ion brings the PAPS molecule closer to
ADP when compared to the position of the APS
molecule in the APS–APS complex structure. This
shift, of ∼0.7 Å, is due to the aforementioned
bridging character of the magnesium ion acting to
bind both the β-phosphate group of ADP and the 3′-
phosphate group of PAPS (Figure 4(b)).
N-terminal residues
We could model all of the APSK residues present
in the construct (residues 25–227). The five most
N-terminal residues have not been observed before
in any APS-kinase structure. These residues show
clear density in the omit maps (Figure 5(a)) and are
in the extended conformation. This N-terminal
region lies at the surface close to the active site of
the neighboring monomer.
All the interactions between the N-terminal
residues and the neighboring monomer occur via
main chain atoms. Specifically, the main chain
amino group of Thr29 interacts with the side-chain
of Asp89, and the backbone NH and carbonyl
moieties of Gln31 interact with the carbonyl and
amino functionalities of the Asn90 side-chain,
respectively (Figure 4(a)). This is consistent with
the low level of sequence conservation observed for
the N terminus (Figure 5(b)). The absence of
interactions between the N terminus and symme-
try-related molecules, along with very similar
conformations for the N-terminal residues in both
the ADP-PAPS and APS-APS structures (despitedifferent crystallization conditions), suggests that
the observed conformation is indeed relevant. By
adopting this conformation, the N terminus is able
to interact with the critical DGDN-loop. However,
we could not detect any appreciable change in the
kinetic behavior of the point mutations N27A,
Q31A, or in a truncation mutant lacking the first
34 N-terminal residues.
Structure with APS
Several monofunctional APS-kinases24–26 and
human bifunctional ATP-sulfurylase/APS-kinase12
have been reported to exhibit pronounced substrate
inhibition with APS. Extensive kinetic studies
performed with the P. chrysogenum enzyme16,25,27
indicate that this inhibition is uncompetitive with
respect to ATP, and that excess of substrate results in
the formation of an abortive complex, where ADP
and APS occupy the active site of the enzyme. Our
kinetic analysis, performed on the APSK domain
of human PAPSS1, supports the formation of the
abortive dead-end complex E-ADP-APS as a mecha-
nism of substrate inhibition for the human enzyme
(data not shown).
However, experiments done on P. chrysogenum
APSK show that 0.4–1.2 mM APS alone provides
significant protection against enzyme inactivation
by 2,4,6-trinitrobenzene sulfonate (a compound that
reacts with free amino groups),17 suggesting the
ability of two APS molecules to bind to the enzyme
and protect the active site from reacting with the
chemical. Indeed, when cocrystallizing the APSK
domain with 3 mM APS and 5 mM MgCl2, we
obtained a structure in which two APS molecules
are bound. Thus, APS occupies both nucleotide-
binding sites of APSK simultaneously. One APS
molecule binds to the ATP-binding site in virtually
the samemanner as ADP (all of the interactions with
the P-loop are maintained) and an additional one
with the APS-binding site. However, different from
the observed mixture of syn and anti conformations
of ADP in the ADP-PAPS structure, in this APS-APS
structure, the APS binding in the ADP binding site is
exclusively in the syn conformation (as is the APS in
the APS binding site).
There are eight molecules in the asymmetric unit
of the APS-APS complex forming four symmetrical
dimers. Six of the eight monomers (chains B, C, D, E,
F, and H) contain the magnesium ion and this
correlates with the active conformation of the
DGDN-loop. In fact, in those monomers of the
APS-APS complex lacking a magnesium ion, the
inactive conformation of the DGDN-loop prevents
the N terminus of the neighboring molecule from
adopting the extended conformation, as described.
The other two monomers (chains A and G) lack this
magnesium, and they exhibit only partial (chain A)
or no occupancy for the active conformation of the
DGDN-loop. Therefore, the largest rmsd between
monomers is observed for chains G and F (0.65 Å for
201 Cα atoms) and the smallest rmsd is observed
between chains C and D (0.26 Å for 203 Cα atoms).
Figure 5. The extended conformation of the N terminus propagates along the neighboring monomer and approaches
the active site. (a) Surface representation of an APSK dimer with one monomer in light blue and one in orange.
Nucleotides, in maroon, are shown as semi-transparent space-filled and ball- and -stick objects, and the magnesium ion is
shown as a yellow sphere. Themost N-terminal residues (25–36) are shown in a ball- and -stick representation surrounded
by the corresponding simulated annealing omit map contoured at 1.5 σ. Residues 37–50 are represented as a ribbon
(α-helix for residues 37–43). See the text for details. (b) Sequence alignment of the N terminus of several APSK domains
from bifunctional enzymes (HUM_1, human PAPSS1; MOU_1, mouse PAPSS1; XENTR, Xenopus tropicalis PAPSS;
HUM_2, human PAPSS2; BRARE; Brachydanio rerio PAPSS; URECA,Urechis caupo PAPSS; CIOIN, Ciona intestinalis PAPSS;
DROME, Drosophila melanogaster PAPSS; CAEEL, Caenorhabditis elegans PAPSS) and the monofunctional Penicillium
chrysogenum (PENIC) APSK enzyme. Note the low level of sequence identity for the first 50 residues. Residues highlighted
in orange correspond to those shown as ball- and -stick in (a).
496 Structure of APS-Kinase Domain of Human PAPSS1The overall structure resembles the previously
discussed ADP-PAPS complex with greatest simi-
larity for chain C (0.45 Å for 204 atoms) and least
similarity for chain A (0.74 Å for 201 atom). Figures
1(b) and 4(b) demonstrate this similarity.
Bearing in mind that ADP and APS have very
similar shapes (are isosteric) and chemical proper-
ties, it is not entirely surprising that APS can bind to
the ADP-binding site. The only difference between
these nucleotides is due to the β-phosphate group in
ADP being replaced with sulfate in APS. Our results
demonstrate that at high concentration APS canindeed bind in the ADP site. Moreover, the binding
of APS to this site can mimic the ability of ATP-ADP
to induce the conformational changes responsible
for the formation of the APS-binding site, enabling
APS association. Although this complex can be seen
as representing the APS inhibitory complex, it was
formed using a high concentration of APS (3 mM).
The much smaller value for inhibitory constants
(about 50 μM) of APS12,16,26,28,29 argue that such an
APS-APS complex is of less importance in the
physiological context in comparison to an ADP-
APS complex.
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Here, we report the crystal structure of the APS
kinase domain of the human PAPSS1 enzyme in
complex with the product nucleotides ADP and
PAPS, and in complex with two substrate molecules
of APS. Both structures are characterized by a
symmetrical dimer, in contrast to the homodimeric,
non-symmetrical complex reported in the context of
the full-length enzyme.13 Harjes et al. observed an
APSK domain with one monomer occupied by
ADP (and APS after soak), while the other mono-
mer wasis vacated. They assigned these differences
to an intrinsic property of the human protein;
specifically, to a lack of one of the internal hydrogen
bonds within the P-loop due to the substitution of
Ser (in P. chrysogenum) with Ala (in the human
enzyme). However, the fact that we were able to
observe a symmetrical dimer (obtained under
different crystallization conditions that resulted in
two crystal forms), analogous to that observed in
the monofunctional P. chrysogenum enzyme, demon-
strates that both active sites can be occupied
identically at the same time in the human APSK
domain. Consistent with this result is the recent
structure of the APSK domain of human PAPSS2,
where a symmetrical dimer was observed. The
identical P-loop sequence between PAPSS1 and
PAPSS2 argues against this loop as the cause of
dimer asymmetry observed in the human bifunc-
tional PAPSS1 structure.
Our structures highlight four major novel fea-
tures: (i) they provide information on the binding of
the reaction product PAPS, (ii) they elucidate the
active conformation of the Michaelis product com-
plex (ADP-Mg plus PAPS), (iii) they show binding of
the magnesium ion that induces a conformational
change in the DGDN-loop, and (iv) they reveal the
extended conformation of the N-terminal region of
the protein. All of these findings are inter-related.
The ability to crystallize with PAPS in the active
site allowed us to identify residues involved in the
binding of the transferred phosphoryl group. Not
surprisingly, interactions between the site harboring
the 3′-phosphate group of PAPS, occupied pre-
viously by the γ-phosphate group of ATP, are
supplied mainly by the P-loop (Ser61 and Lys65),
but also by the highly conserved lid residue Lys171
(being analogous to the lid Arg in nucleoside
monophosphate kinases22), emphasising the impor-
tance of this residue in the phosphoryl transfer
reaction. Together, the adenine stacking interaction
of Arg168 and the aforementioned interaction of
Lys171 make the sole connection between phos-
phoryl donor nucleotide and the mobile lid region of
the protein. Although the electron density for the lid
can be modeled in the structures with ADP and
APS,13,19 as well as in our structure with two APS
molecules (i.e. in structures missing the γ-phosphate
group, or the 3′-phosphate group), the conformation
of the lid region in not completely rigid. This is
demonstrated by the fact that the lid adopts several
slightly different conformations in our structurewith two APS molecules bound in the active site.
This implicates Lys171 as the final interaction from
the lid region needed for the formation of a
functional active site.
The presence of the magnesium ion in the ADP-
PAPS structure, as well as in several monomers of
the APS-APS structure, identifies Asp87 and Asp89
unambiguously as residues of a Walker B motif
sequence. The motif is required for magnesium
binding by supplying a carboxylic acid residue that
positions a water molecule that ligates the metal.
This observation rationalizes mutational studies that
identified the DGDN-loop as a structural motif
indispensable for the activity of the enzyme,23 as
well as the effect of the mutation G78R in PAPSS2
that results in the brachymorphic defect in mice. On
the basis of the structures described here, mutation
of the glycine will be detrimental to activity for two
reasons: one, by decreasing the flexibility of the
loop, the required conformational change will be
hindered, and this will prevent the binding of the
essential magnesium ion. Two, any residue larger
than an alanine will sterically clash with PAPS. The
distance from the Cβ atom of an alanine modeled at
that position to the α-phosphate group of PAPS is
less than 2.8 Å. Also, interactions between the γ-
phosphate group, the magnesium ion, and the
DGDN-loop may have a role in promoting the
conformational changes that shape the APS-binding
site. This fact rationalizes the observed ordered
binding mechanism.
In both the ADP-PAPS and the APS-APS complex
structures, the carboxylic group of Asp89 interacts
with the 2′ and 3′-hydroxyl groups of PAPS and
APS, respectively. These interactions are required
for the proper orientation (2′-endo, 3′-exo) of the
sugar ring for the phosphorylation by ATP (Figure
4(b)). Moreover, this interaction reveals that Asp89
could function as the general base by abstracting a
proton from the 3′-hydroxyl group of APS. This
would increase the nucleophilicity of the 3′-group
and promote the nucleophilic attack on the γ-
phosphate group of ATP. This proposed mechanism,
involving Asp89, is in better agreement with the
structural data in comparison to an alternative
model, which proposed the P-loop Ser61 as the
general base.19 Once Asp89 becomes protonated, its
interactions with the sugar are weakened, promot-
ing the relaxation of the DGDN-loop and subse-
quent dissociation of PAPS from the active site.
We were successful in trapping the complex of
ADP-Mg and PAPS due to the extended conforma-
tion adopted by the N terminus. This conformation
sterically prevents the DGDN-loop from returning to
its inactive position (Figure 4(a)). In fact, by inter-
actingwith theDGDN-loop, theN terminus seems to
stabilize the bound state of the products in our
structure. Surprisingly, mutational analysis of this
region does not affect the steady-state kinetic
parameters of the enzyme. Neither the point muta-
tions N27A and Q31A, nor the complete deletion of
the first 34 N-terminal residues had any effect on the
kinetics of the APSK domain (Supplementary Data
498 Structure of APS-Kinase Domain of Human PAPSS1Table S1). A similar deletion mutant generated in the
context of the full-length protein also reported no
change in the kinetic parameters.30 This suggests
that, while positioned close to the active site, this
N-terminal region of the APSK domain does not play
a critical role in catalysis.
A significant aspect of the work is that we were
successful in trapping the Michaelis complex of the
APS-kinase reaction. Notably, this was accom-
plished without resorting to substrate analogs (e.g.
employing a non-hydrolyzable analog), removal of
the essential magnesium ion (e.g. by addition of the
chelator EDTA), or by enzyme-inactivating muta-
tions, three strategies that can be employed to allow
the visualization of a Michaelis complex of an
enzyme catalyzing phosphoryl transfer. Thermody-
namic properties of PAPSS played an important part
in our ability to solve the structure of the product
complex composed of a molecule of ADP, a molecule
of PAPS, and a magnesium ion. The equilibrium in
solution of the APS-kinase reaction favors the
products by a factor of over 1000. This is due to the
fact that during the reaction the higher energy phos-
phoanhydride bond of ATP (ΔG°'=−32.2 kJ/mol) is
broken and the lower energy phosphate ester
(ΔG°'=−13.8 kJ/mol) on the 3′-hydroxyl group of
APS is formed.We can conclude that the equilibrium
on the enzyme mirrors that in solution and, thus,
favors the products. In summary, we were able to
observe the Michaelis products complex of the
enzyme due to two facts. First, the thermodynamics
of the system, which favors the products over the
substrates. Second, the conformation of the N
terminus, which “locks” the protein in a conforma-
tion that prevents product release.
The Michaelis products structure exposes all of the
amino acid side-chains that are important in catalyz-
ing phosphoryl transfer. In addition, the DGDN-loop
is stabilized in its active conformation. Most impor-
tantly, the observation of themagnesium ion bridging
the β-phosphate group of ADP and the transferred
γ-phosphate group, now located at the 3′-position of
PAPS, permits the assignment of at least two
catalytic roles for the magnesium ion: one, stabiliza-
tion of the additional negative charge that forms in
the transition state of the transferred phosphoryl
group, and two, guiding the phosphoryl group from
the donor ATP to the acceptor APS. Together, these
findings reveal the intricacies of phosphoryl transfer
catalyzed by the APSK domain of human PAPSS1.Materials and Methods
Protein expression and purification
In order to increase the chances of crystallization, we
have examined previously solved crystal structures and
conservation of the N-terminal residues among different
APS-kinases (Figure 5(b)). We noticed that the first 25
residues are not conserved between APSK domains of
bifunctional PAPSS and are not present in the monofunc-
tional P. chrysogenumAPSK. This observation prompted usto design an APSK domain construct lacking the first 25
residues. As the terminal residue for our construct we
have chosen residue 227 of human PAPSS1 based on
analysis of P. chrysogenum structures.
The APS-kinase domain (25–227 amino acid residues) of
the PAPSS1 coding region31 was cloned as a glutathione-S-
transferase fusion in the bacterial expression vector pGEX-
RB,32 in which the thrombin cleavage site was replaced by
a Tobacco etch virus site. Expression was induced by
0.1 mM IPTG and Escherichia coli BL-21 Codon-Plus
(Stratagene) cells were grown overnight at 22 °C. After
cell sonication, the soluble fraction was subjected to a
Glutathione-Sepharose Fast Flow column (Pharmacia),
washed with 50 mM Tris–HCl (pH 7.5), 200 mM KCl,
5 mMMgCl2, 1 mMEDTA and eluted with the same buffer
containing 10 mM glutathione. Eluted protein was cut
overnight with Tobacco etch virus protease, while
glutathione was dialyzed out. Uncut protein was removed
by reloading the protein on the Glutathione-Sepharose
Fast Flow column and collecting the cut protein in the
flow-through. As a final step of purification, APS kinase in
the above buffer was subjected to gel-filtration chromato-
graphy using Superdex 200 (Pharmacia). Almost all of the
protein was eluted from the column as a peak correspond-
ing to ∼50 kDa, indicating that APSK forms a dimer in
solution. During the purification procedure, the concen-
tration of DTTwas maintained at 5 mM. The total yield of
the protein from 6 L of bacterial culture was ∼1.5 g.
Purified protein was frozen at −80 °C. Before crystal-
lization, the protein was dialyzed against 25 mM Tris–HCl
(pH 7.5), 25 mM KCl, 7 mM DTT.
Crystallization and X-ray data collection
Crystals were grown at room temperature using
hanging drops containing equal volumes of protein and
reservoir solution (2 μL+2 μL). For generating the APS
complex, the protein solution contained 5–8 mg/ml of
Δ25N APSK, 3 mM APS and 5 mM MgCl2, while the
reservoir contained 18–20% (w/v) PEG 3350 and 0.25 M
calcium acetate. Rectangular, birefringent crystals
appeared overnight. Crystals were very sensitive to
manipulation so, as cryoprotectant, grains of glucose
were added directly to the drop and left to dissolve for
5–10 min. Crystals were then frozen in liquid nitrogen.
For the ADP-PAPS complex, the protein solution
contained 6 mg/ml of Δ25N APSK, 2 mM PAPS, 2 mM
ADP and 5 mMMgCl2, while the reservoir contained only
0.2–0.4 mM ammonium dihydrogen phosphate. Crystals
were transferred stepwise to a mother liquor solution
containing 30% (w/v) glucose, and then frozen in liquid
nitrogen. The high-resolution limit for the data set
collected on these crystals was restricted by the crystal-
to-detector distance. In addition to the nucleotides and
magnesium ions, four phosphate groups were modeled
bound at the surface of the protein. We could also model
two extra N-terminal residues (Met and His) remaining
after cleavage by Tobacco etch virus.
Data were collected at Southeast Regional Collaborative
Access Team (SER-CAT) 22-BM beamline at the Advanced
Photon Source, Argonne National Laboratory and pro-
cessed with the XDS program package.33
Steady-state kinetics
The APSK enzymatic assay in the forward reaction was
performed by monitoring the rate of ADP formation using
a pyruvate kinase/lactate dehydrogenase-coupled spec-
499Structure of APS-Kinase Domain of Human PAPSS1trophotometric assay, which measures the decrease in
absorbance at 340 nm due to the oxidation of NADH. The
assay was performed with 200–400 nM enzyme in 50 mM
Tris–HCl (pH 7.5), 100 mM KCl, 2.5 mM MgCl2, 0.25 mM
EDTA, 1.0 mM ATP, 0.4 mM phosphoenolpyruvate,
0.2 mM NADH. The concentration of APS was varied
between 2 μM and 100 μM. The reaction mixture was left
to equilibrate for 10 min at 37 °C to allow for the
consumption of traces of ADP present in the ATP stock
solution. APSK was added to trigger the reaction. All
measurements were made in triplicate at 37 °C using a
Varian Cary 50 Bio UV-visible spectrophotometer.Acknowledgements
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